Ondansetron hydrochloride dihydrate (ondansetron hydrochloride dihydrate; GR 38032 hydrochloride dihydrate; SN 307 hydrochloride dihydrate)

Name: Ondansetron hydrochloride dihydrate (ondansetron hydrochloride dihydrate; GR 38032 hydrochloride dihydrate; SN 307 hydrochloride dihydrate)
Rating: 5 (1 reviews)

Cat No.:V71163

COA Product Data Instructions for use SDS

Ondansetron (GR 38032) HCl dehydrate is an orally bioavailable, selective and competitive 5-HT3 receptor antagonist (BBB (blood-brain barrier) permeable (penetrable)).

Ondansetron hydrochloride dihydrate (ondansetron hydrochloride dihydrate; GR 38032 hydrochloride dihydrate; SN 307 hydrochloride dihydrate) Chemical Structure CAS No.: 103639-04-9
Product category: 5-HT Receptor

This product is for research use only, not for human use. We do not sell to patients.

Size	Price	Stock	Qty
250mg
500mg
1g
5g
Other Sizes

1-708-310-1919 sales@invivochem.com

Other Forms of Ondansetron hydrochloride dihydrate (ondansetron hydrochloride dihydrate; GR 38032 hydrochloride dihydrate; SN 307 hydrochloride dihydrate):

Official Supplier of:

Top Publications Citing lnvivochem Products

Nature 2025, 643(8070):192-200.

Nature 2024 Dec 18.

Nature 2021, 597(7874):119-125.

Cell 2020,183:1202-1218.e25.

Science Adv 2022: 8, eabm9427.

Nat Neurosci 2024, 27:1468-1474.

Science Adv 2025, 11(33):eadr5199.

Nat Metab 2024, 6: 1108-1127.

Cell Stem Cell 2024, 31:106-126.e13.

Nature 597, 119–125 (2021)

Cell Stem Cell 2020,26(6):845-861.e12.

Science Trans Med 2023,15(701):eadd7872.

STTT 2023,8(1):91.

Cell Reports 2023,42(4):112313

Science Trans Med 2023, 15: eadd7872.

Cancer Cell 2021,39(4):529-547.e7.

Cancer Discov 2022,12(4):1106-1127.

Immunity 2024,57:2651-2668.e12.

Immunity 2023,56(3):620-634.e11.

J Am Chem Soc 2022,144:21831-21836.

Cell 2020,183:1202-1218.e25.

Science Adv 2022:8,eabm9427.

Nature 2021,597(7874):119-125.

Cell 2020,183:1202-1218.e25.

PNAS Nexus 2022,1(3):pgac063.

ACS Nano 2023,17(10):9110-9125.

Biomaterial 2023 Sep16:302:122333.

Product Description
Product Application
Bioactivity & Protocols
Physicochemical Properties
Solubility Data
Calculators
Clinical Trial Information

Product Description

Ondansetron (GR 38032) HCl dehydrate is an orally bioavailable, selective and competitive 5-HT3 receptor antagonist (BBB (blood-brain barrier) permeable (penetrable)). Ondansetron HCl dehydrate is used to prevent nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery.

Product Application

Overview
Ondansetron HCl dehydrate (GR 38032) is a highly selective, orally bioavailable 5-HT3 receptor antagonist. It effectively crosses the blood-brain barrier, allowing modulation of central and peripheral serotonergic signaling. As a competitive antagonist, Ondansetron blocks 5-HT3 receptor–mediated neurotransmission, which is critical in regulating nausea and vomiting pathways. Its pharmacological profile makes it a valuable tool for both preclinical and translational research on serotonin-mediated processes, including emesis, gastrointestinal signaling, and central nervous system studies.
The compound’s high selectivity for 5-HT3 receptors over other serotonin receptor subtypes minimizes off-target effects, enabling precise investigation of receptor-specific signaling and behavioral responses. This property is particularly relevant in research involving chemotherapeutic-induced nausea, motion sickness models, and neuropharmacology studies where serotonergic regulation plays a central role.

Mechanistic Insight
Ondansetron functions as a competitive antagonist at the 5-HT3 receptor, directly competing with endogenous serotonin for binding sites. By blocking receptor activation, it prevents the depolarization of neurons in the vomiting reflex arc and gastrointestinal tract. Its ability to permeate the blood-brain barrier ensures that central 5-HT3–mediated pathways are also modulated, providing a comprehensive tool to dissect serotonergic signaling in both peripheral and central contexts.
The receptor selectivity and competitive mechanism make Ondansetron suitable for dose-dependent studies where graded inhibition of 5-HT3–mediated responses is needed. Researchers can explore receptor occupancy, desensitization, and downstream signaling cascades in neuronal and gut models.

Biological and Therapeutic Relevance
Ondansetron is widely used as a reference compound in models of nausea and vomiting, including chemotherapy- and radiation-induced emesis. Its activity in blocking 5-HT3 receptors provides insight into serotonergic modulation of gastrointestinal motility, visceral afferent signaling, and central vomiting pathways. Beyond emesis, Ondansetron serves as a research tool for studying serotonergic regulation in psychiatric, neurological, and gastrointestinal contexts. Its BBB permeability allows evaluation of central serotonergic mechanisms that influence mood, anxiety, and cognitive processes.

Research Applications
Ondansetron can be utilized for:
• Investigating 5-HT3 receptor–mediated neuronal and gastrointestinal signaling • Studying emesis and nausea in preclinical models • Evaluating central versus peripheral serotonergic effects • Exploring receptor desensitization, occupancy, and downstream signaling • Serving as a reference antagonist in serotonin pathway pharmacology

Handling and Storage
Store Ondansetron HCl dehydrate as a solid at -20°C in a dry, light-protected environment. Solutions may be prepared in aqueous or organic solvents and stored at -80°C for short-term use. Proper handling ensures compound stability and reproducibility in experimental settings.
For quotes or guidance on incorporating Ondansetron into research studies, contact InvivoChem.

Biological Activity I Assay Protocols (From Reference)

Targets	5-HT3 Receptor
ln Vivo	In the radiation-induced pica model, ondansetron hydrochloride dehydrate (2 mg/kg; ip; single) prevents radiation sickness when combined with dexamethasone (2 mg/kg) and CP-99,994 (15 mg/kg)[1].
Animal Protocol	Animal/Disease Models: Male mice of ICR strain (8weeks old; 30-36 g; radiation-induced pica model (kaolin ingestion behavior “pica” may be analogous to nausea and vomiting in mice))[1]. Doses: 2 mg/kg Route of Administration: intraperitoneal (ip) injection; single. Experimental Results: Slightly decreased the radiation-induced kaolin consumption by dexamethasone to 48% of the control. demonstrated good activity of blocking radiation sickness by combining with Dexamethasone (2 mg/kg) and CP-99,994 (15 mg /kg).
ADME/Pharmacokinetics	Metabolism / Metabolites Liver half-life: 5.7 hours
Toxicity/Toxicokinetics	Effects During Pregnancy and Lactation ◉ Overview of Use During Lactation Ondansetron is commonly used to relieve nausea during and after cesarean section, usually at an intravenous dose of 4 to 8 mg. Use of ondansetron during and after cesarean section does not appear to affect the initiation of breastfeeding. No adverse reactions have been reported in infants of women who received ondansetron postpartum, nor in pharmacokinetic studies. Studies on the use of ondansetron in postpartum lactating women are insufficient, but the drug is approved for use in infants up to 1 month old. Computer models show that drug concentrations in breast milk are far below this dose. No special precautions are required. ◉ Effects on Breastfed Infants A pharmacokinetic study of 78 women who received intravenous ondansetron postpartum showed no adverse reactions in their breastfed infants. ◉ Effects on Lactation and Breast Milk A randomized, double-blind study compared the effects of placebo versus intravenous 4 mg ondansetron after cesarean section in preventing postoperative nausea and vomiting. There was no difference in the time to first breastfeeding between the two groups. A retrospective study compared three medication regimens in women who underwent cesarean section: dexmedetomidine before anesthesia and during delivery (n = 115), saline before anesthesia and during delivery, and dexmedetomidine postpartum (n = 109), and saline before anesthesia and during delivery (n = 168). All women received 4 mg ondansetron as needed, prior to suture removal. The mean total ondansetron intake ranged from 6 mg to 9 mg across all groups. The time to first lactation was similar across all groups (25 to 28 minutes).
References	[1]. Ondansetron, dexamethasone and an NK1 antagonist block radiation sickness in mice. Pharmacol Biochem Behav. 2005 Sep;82(1):24-9. [2]. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs. 1996 Nov;52(5):773-94.
Additional Infomation	Ondansetron hydrochloride belongs to the carbazole class of drugs. Ondansetron hydrochloride is the hydrochloride salt of the racemic mixture of ondansetron. Ondansetron is a carbazole derivative and a selective competitive 5-HT3 receptor antagonist with antiemetic activity. Although its mechanism of action is not fully elucidated, ondansetron appears to competitively block the action of 5-HT3 receptors in the peripheral gastrointestinal tract and in the postmedula medulla oblongata (the region containing the chemoreceptor trigger zone (CTZ) of the central nervous system), thereby inhibiting nausea and vomiting induced by chemotherapy and radiotherapy. A competitive 5-HT3 receptor antagonist. It is effective in treating nausea and vomiting induced by cytotoxic chemotherapy drugs (including cisplatin) and has been reported to have anti-anxiety and antipsychotic effects. See also: Ondansetron hydrochloride (note moved to).

These protocols are for reference only. InvivoChem does not independently validate these methods.

Physicochemical Properties

Molecular Formula	C18H24CLN3O3
Molecular Weight	365.85
Exact Mass	365.15
CAS #	103639-04-9
Related CAS #	Ondansetron;99614-02-5;Ondansetron hydrochloride;99614-01-4
PubChem CID	59774
Appearance	White to off-white solid powder
Density	1.1±0.1 g/cm3
Boiling Point	267.0±9.0 °C at 760 mmHg
Melting Point	231-232ºC
Flash Point	144.9±5.1 °C
Vapour Pressure	0.0±0.5 mmHg at 25°C
Index of Refraction	1.523
LogP	-0.37
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	2
Heavy Atom Count	25
Complexity	440
Defined Atom Stereocenter Count	0
SMILES	CC1=NC=CN1CC2CCC3=C(C2=O)C4=CC=CC=C4N3C.O.O.Cl
InChi Key	VRSLTNZJOUZKLX-UHFFFAOYSA-N
InChi Code	InChI=1S/C18H19N3O.ClH.2H2O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2;;;/h3-6,9-10,13H,7-8,11H2,1-2H3;1H;2*1H2
Chemical Name	9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one;dihydrate;hydrochloride
HS Tariff Code	2934.99.9001
Storage	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. (2). This product is not stable in solution, please use freshly prepared working solution for optimal results.
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Solubility Data

Solubility (In Vitro)

DMSO: 100 mg/mL (273.34 mM)
H2O: 16.67 mg/mL (45.57 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.5 mg/mL (6.83 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.5 mg/mL (6.83 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

(Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.7334 mL	13.6668 mL	27.3336 mL
	5 mM	0.5467 mL	2.7334 mL	5.4667 mL
	10 mM	0.2733 mL	1.3667 mL	2.7334 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Mass

Concentration

Volume

Molecular Weight*

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

Calculate the Mass of a compound required to prepare a solution of known volume and concentration
Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume

See Example

An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?

Enter 350.26 in the Molecular Weight (MW) box
Enter 10 in the Concentration box and choose the correct unit (mM)
Enter 5 in the Volume box and choose the correct unit (mL)
Click the “Calculate” button
The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Concentration (Start)

Volume (Start)

Concentration (End)

Volume (End)

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:

Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
Enter 25 into the Concentration (End) box and select the correct unit (mM)
Enter 25 into the Volume (End) box and choose the correct unit (mL)
Click the “Calculate” button
The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box

Molecular formula

Total molecular weight

g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4 c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
Click the “Calculate” button
The answer appears in the Volume (to add to vial) box

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)

Dosage mg/kg

Average weight of animals g

Dosing volume per animal μL

Number of animals

Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)

% DMSO

% Tween 80

% ddH₂O

Calculation results

Working concentration： mg/mL；

Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O，mix and clarify.

Note： (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.

Clinical Trial Information

Title:Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)
Status:Completed
updateDate:2025-12-05
Ctid:NCT02473042

Link: https://clinicaltrials.gov/ct2/show/NCT02473042

Conditions:Post-Operative Nausea and Vomiting|Breast Cancer
Interventions:Pepcid
Phase:N/A

Title:Multimodal Analgesia Effect on Post Surgical Patient
Status:Active, not recruiting
updateDate:2025-08-08
Ctid:NCT04240626

Link: https://clinicaltrials.gov/ct2/show/NCT04240626

Conditions:Obesity, Morbid|Surgery|Bariatric Surgery Candidate
Interventions:Tylenol Suspension
Phase:Phase 4

Title:PROUD Study - Preventing Opioid Use Disorders
Status:Terminated
updateDate:2023-06-22
Ctid:NCT04766996

Link: https://clinicaltrials.gov/ct2/show/NCT04766996

Conditions:Anesthesia|Opioid Use
Interventions:Toradol
Phase:Phase 4

View More

Title:Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With Zofran
Status:Completed
updateDate:2022-04-04
Ctid:NCT03973047

Link: https://clinicaltrials.gov/ct2/show/NCT03973047

Conditions:Nausea
Interventions:Placebo
Phase:Phase 1

Title:Pain Management After Shoulder Arthroplasty
Status:Unknown status
updateDate:2021-05-04
Ctid:NCT04872270

Link: https://clinicaltrials.gov/ct2/show/NCT04872270

Conditions:Caffeine|Pain, Joint
Interventions:Zofran 4Mg Tablet
Phase:Phase 3

Title:Crossover Study Comparing Ondansetron Orally Dissolving Film Strip (ODFS) With Zofran Orally Disintegrating Tablets
Status:Completed
updateDate:2020-07-29
Ctid:NCT01217190

Link: https://clinicaltrials.gov/ct2/show/NCT01217190

Conditions:Nausea and Vomiting, Postoperative|Nausea With Vomiting Chemotherapy-Induced
Interventions:Zofran (ODT)
Phase:Phase 1/Phase 2

Title:BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis
Status:Completed
updateDate:2019-02-20
Ctid:NCT02246439

Link: https://clinicaltrials.gov/ct2/show/NCT02246439

Conditions:Gastroenteritis|Gastritis
Interventions:Placebo Oral Tablet
Phase:Phase 3

Title:Study of Buprenorphine Sublingual Spray Versus Standard of Care Narcotic Therapy for the Treatment of Post-Operative Pain
Status:Completed
updateDate:2018-10-29
Ctid:NCT03254459

Link: https://clinicaltrials.gov/ct2/show/NCT03254459

Conditions:Pain, Postoperative
Interventions:Zofran
Phase:Phase 2

Title:Decreasing Narcotics in Advanced Pelvic Surgery
Status:Completed
updateDate:2016-08-17
Ctid:NCT02110719

Link: https://clinicaltrials.gov/ct2/show/NCT02110719

Conditions:Narcotic Use|Pain|Constipation|Nausea
Interventions:zofran
Phase:Phase 4

Title:The Effect of Dexamethasone in Combination With Paracetamol and Ibuprofen on Postoperative Pain After Spine Surgery
Status:Completed
updateDate:2015-10-27
Ctid:NCT01953978

Link: https://clinicaltrials.gov/ct2/show/NCT01953978

Conditions:Pain
Interventions:Ibuprofen
Phase:Phase 4

Title:The Effect of Chlorzoxazone on Moderate to Severe Postoperative Pain After Spine Surgery
Status:Completed
updateDate:2015-09-17
Ctid:NCT01933542

Link: https://clinicaltrials.gov/ct2/show/NCT01933542

Conditions:Chlorzoxazone|Postoperative Pain
Interventions:Zofran
Phase:Phase 4

Title:Droperidol and Cardiac Repolarization
Status:Completed
updateDate:2013-08-07
Ctid:NCT01819857

Link: https://clinicaltrials.gov/ct2/show/NCT01819857

Conditions:Cardiac Repolarization
Interventions:Zofran 8 mg
Phase:Phase 4

Title:Improving Tolerance of Treatment of Pulmonary MAC Infections
Status:Withdrawn
updateDate:2013-04-04
Ctid:NCT01719042

Link: https://clinicaltrials.gov/ct2/show/NCT01719042

Conditions:Mycobacterium Avium Complex|Adverse Effects
Interventions:Ensure
Phase:Phase 2

Title:Bioavailability Study of Ondansetron 24 mg Orally Disintegrating Tablets Under Fasting Conditions
Status:Completed
updateDate:2008-04-16
Ctid:NCT00659074

Link: https://clinicaltrials.gov/ct2/show/NCT00659074

Conditions:Healthy
Interventions:Zofran
Phase:Phase 1

Title:Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fasting Conditions
Status:Completed
updateDate:2008-04-11
Ctid:NCT00654277

Link: https://clinicaltrials.gov/ct2/show/NCT00654277

Conditions:Healthy
Interventions:Zofran
Phase:Phase 1

Title:Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fed Conditions
Status:Completed
updateDate:2008-04-11
Ctid:NCT00653458

Link: https://clinicaltrials.gov/ct2/show/NCT00653458

Conditions:Healthy
Interventions:Zofran
Phase:Phase 1

Title:A Multicenter, Randomized, Single-blind, Active-controlled, Parallel Group, Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of a Single Intravenous (6 mg, 12 mg, 18 mg, 24 mg or 36 mg) Dose of the Neurokinin-1 Receptor Antagonist, Vestipitant (GW597599), Compared with a Single 4 mg Intravenous Ondansetron Hydrochloride Dose for the Treatment of Breakthrough Post-Operative Nausea and Vomiting after Failed Prophylaxis with an Ondansetron-Containing Regimen in Patients Undergoing Non-Emergency Surgical Procedures
Status:Prematurely Ended
Date:2012-04-05
Eudractnumber:2011-005216-28

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-005216-28

Condition:Post-operative nausea and vomiting (PONV)
Phase:Phase 2

Title:A multicenter, randomized, double-blind, parallel group study to evaluate the efficacy and safety of two different doses of palonosetron compared to ondansetron in the prevention of CINV in pediatric patients undergoing single and repeated cycles of MEC or HEC.
Status:Completed, Ongoing
Date:2011-08-04
Eudractnumber:2010-022872-30

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022872-30

Condition:Study to evaluate the efficacy and safety of two different doses of palonosetron compared to ondansetron in the prevention of CINV in pediatric patients undergoing single and repeated cycles of MEC or HEC
Phase:Phase 3

Title:A Multicenter, Double-blind, Double-dummy, Randomized, Parallel Group, Stratified Study to Evaluate the Efficacy and Safety of a Single IV Dose of Palonosetron Compared to a Single IV Dose of Ondansetron to Prevent Postoperative Nausea and Vomiting in Pediatric Patients
Status:Completed
Date:2011-05-23
Eudractnumber:2010-022971-79

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2010-022971-79

Condition:Postoperative nausea and vomiting (PONV)
Phase:Phase 3

Title: A comparative double-blind placebo-controlled study between alizapride and ondansetron for the prevention of postoperative nausea and vomiting.
Status:Completed
Date:2008-09-05
Eudractnumber:2008-004789-20

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-004789-20

Condition:Prevention of post-operative nausea and vomiting.
Phase:Phase 4

Title:Ondansetronin vaikutus parasetamolin kipulääkevasteeseen tähystyksen kautta tehtävän kohdunpoiston yhteydessä
Status:Completed
Date:2007-11-09
Eudractnumber:2007-005311-25

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2007-005311-25

Condition:Tähystysleikkauksen jälkeinen kipu
Phase:Phase 4

Title:Brush-evoked allodynia in patients with peripheral neuropathy before and following intravenous infusion of ondansetron. A randomised, double-blind, placebo controlled, cross-over study.
Status:Completed
Date:2007-01-03
Eudractnumber:2006-000526-31

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000526-31

Condition:Peripheral neuropathy
Phase:Phase 4

Title:A Randomized, Double-Blind, Parallel-Group Study Conducted Under In-House Blinding Conditions to Determine the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Moderately Emetogenic Chemotherapy (Study #2)
Status:Completed
Date:2006-11-23
Eudractnumber:2006-003512-22

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-003512-22

Condition:Chemotherapy-induced Nausea and Vomitting
Phase:Phase 3

Title:A Phase III Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group Study of the Efficacy and Safety of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, Casopitant, administered in Combination with ZOFRAN and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Highly Emetogenic Cisplatin-Based Chemotherapy
Status:Completed
Date:2006-09-11
Eudractnumber:2006-002033-21

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-002033-21

Condition:Chemotherapy induced nausea and vomiting (CINV) due to Highly Emetogenic Chemotherapy (HEC)
Phase:Phase 3

Title:A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, Casopitant (GW679769) in Combination with Ondansetron and Dexamethasone for the Prevention of Nausea and Vomiting Induced By Moderately Emetogenic Chemotherapy
Status:Completed
Date:2006-07-24
Eudractnumber:2006-000781-37

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000781-37

Condition:Chemotherapy induced nausea and vomiting (CINV) due to Moderately Emetogenic Chemotherapy (MEC)
Phase:Phase 3

Title:A Randomized, Double-Blind, Active Comparator-Controlled, Parallel-Group Study
Status:Prematurely Ended
Date:2006-06-12
Eudractnumber:2006-001761-42

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-001761-42

Condition:Postoperative Nausea and Vomiting
Phase:Phase 3

Title:A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50 mg Oral Dosing with the Neurokinin-1 Receptor Antagonist GW679769 for the Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status:Completed
Date:2006-03-29
Eudractnumber:2005-005856-42

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005856-42

Condition:Postoperative Nausea and Vomiting (PONV)
Phase:Phase 3

Title:A Phase III Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of the 30 mg Intravenous Formulation of the Neurokinin-1 Receptor Antagonist GW679769 for Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
Status:Completed
Date:2006-03-20
Eudractnumber:2005-005855-16

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2005-005855-16

Condition:Postoperative Nausea and Vomiting (PONV)
Phase:Phase 3

Title:A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Oral Neurokinin-1 Receptor Antagonist, GW679769, When Administered with Intravenous Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting (PONV) and Post-discharge Nausea and Vomiting (PDNV) in Female Subjects
Status:Completed
Date:2005-05-20
Eudractnumber:2004-000370-31

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000370-31

Condition:Post Operative Nausea and Vomiting (PONV)Post Discharge Nausea and Vomiting (PDNV)
Phase:Phase 2

Title:A Multicentre, Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel Group, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Oral (25 mg) and Intravenous (3 mg and 18 mg) Formulations of the Neurokinin-1 Receptor Antagonist, GW597599, When Administered with Intravenous Ondansetron Hydrochloride for the Prevention of Post-operative Nausea and Vomiting and Post-discharge Nausea and Vomiting in Female Subjects with Known Risk Factors for PONV
Status:Completed
Date:2005-02-08
Eudractnumber:2004-001021-22

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001021-22

Condition:Post Operative Nausea and Vomiting (PONV)Post Discharge Nausea and Vomiting (PDNV)
Phase:Phase 2

Title:A multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of oral dosing with GW679769 (50 mg or 150 mg) for 3 consecutive days in conjunction with a single intravenous dose of ondansetron for the prevention of post-operative and post-discharge nausea and vomiting in at risk females undergoing laparoscopic/laparotomic surgical procedures.
Status:Completed
Date:2005-02-01
Eudractnumber:2004-000369-37

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000369-37

Condition:Post Operative Nausea and Vomiting (PONV)Post Discharge Nausea and Vomiting (PDNV)
Phase:Phase 2

Title:
Status:Completed
Date:2005-01-25
Eudractnumber:2004-001020-20

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-001020-20

Condition:Chemotherapy Induced Nausea and Vomiting (CINV) 0 Moderately Emetogenic Chemotherapy (MEC)
Phase:Phase 2

Title:A Phase II Multicentre, Randomised, Double-Blind, Placebo and Active-Controlled, Dose-Ranging, Parallel Group Study of the Safety and Efficacy of The Oral Neurokinin-1 Receptor Antagonist, GW679769 When Administered at daily doses of 50 mg, 100 mg, and 150 mg Oral Tablets in Combination with Ondansetron Hydrochloride and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Highly Emetogenic Cisplatin-based Chemotherapy.
Status:Completed
Date:2005-01-25
Eudractnumber:2004-000371-34

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2004-000371-34

Condition:Chemotherapy-Induced Nausea and Vomiting (CINV) - Highly Emetogenic Chemotherapy (HEC)
Phase:Phase 2

Title:Efficacité de l'ondansetron sur les vomissements dus aux gastroentérites aiguës pédiatriques en période hivernale
Status:Ongoing
Date:
Eudractnumber:2011-004372-11

Link: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2011-004372-11

Condition:Enfants de 6 mois à 15 ans inclus, consultant aux urgences pour gastroentérite aiguë et ayant eu au moins 3 vomissements non bilieux, non sanglants dans les 12 heures qui précèdent la consultation.
Phase:Phase 3